多发性硬化脊髓萎缩纵向评估:GBSI与CSA方法比较
本研究在282例多发性硬化患者和82名对照中比较了基于配准的GBSI与基于分割的CSA测量脊髓萎缩的纵向变化。GBSI在区分患者与对照及残疾进展方面优于CSA,且所需样本量更小,但仍有局限。
要点
- GBSI测量脊髓萎缩的变异性低于CSA,在区分MS患者与健康对照时AUC更高。
- GBSI检测1年60%治疗效应所需样本量显著少于CSA。
- GBSI仍不完美,但可提高多中心研究的统计效力。
核心结论
- 基于配准的GBSI方法比传统基于分割的CSA方法能更好区分MS患者与健康对照,并提高统计效力。
研究设计与样本
- 多中心纵向研究,纳入282例MS患者(52例CIS、196例RRMS、34例PMS)和82名对照,来自8个MAGNIMS中心,基线和1年脊髓3D T1加权成像。
主要发现
- GBSI与CSA测得的年萎缩率相似,但GBSI的测量变异性更小(CIS:-0.95±2.11% vs -1.19±3.67%;RRMS:-1.74±2.57% vs -1.74±4.02%;PMS:-2.29±2.40% vs -1.29±3.20%;对照:0.02±2.39% vs -0.56±3.77%)。
- GBSI区分健康对照与CIS的AUC为0.66 vs 0.53(p=0.03),与RRMS为0.73 vs 0.59(p<0.001),与PMS为0.77 vs 0.53(p<0.001)。
- GBSI区分残疾进展与未进展患者的AUC为0.59 vs 0.50(p=0.04)。
- 检测1年60%治疗效应所需样本量GBSI低于CSA(CIS:106 vs 830;RRMS:95 vs 335;PMS:44 vs 215;power=80%,alpha=5%)。
临床怎么用
- 在多中心MS脊髓萎缩纵向评估中,GBSI可减少测量变异性并提高区分患者与对照及残疾进展的能力。
- GBSI可降低检测治疗效应所需的样本量,有望用于临床试验。
局限性
- GBSI方法仍远非完美,区分残疾进展的AUC仅0.59。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Spinal cord atrophy is a clinically relevant feature of multiple sclerosis (MS), but longitudinal assessments on magnetic resonance imaging using segmentation-based methods suffer from measurement variability, especially in multicenter studies. We compared the generalized boundary shift integral (GBSI), a registration-based method, with a standard segmentation-based method. METHODS: Baseline and 1-year spinal cord 3-dimensional T1-weighted images (1mm isotropic) were obtained from 282 patients (52 clinically isolated syndrome [CIS], 196 relapsing-remitting MS [RRMS], 34 progressive MS [PMS]), and 82 controls from 8 MAGNIMS (Magnetic Resonance Imaging in Multiple Sclerosis) sites on multimanufacturer and multi-field-strength scans. Spinal Cord Toolbox was used for C2-5 segmentation and cross-sectional area (CSA) calculation. After cord straightening and registration, GBSI measured atrophy based on the probabilistic boundary-shift region of interest. CSA and GBSI percentage annual volume change was calculated. RESULTS: GBSI provided similar rates of atrophy, but reduced measurement variability compared to CSA in all MS subtypes (CIS: -0.95 ± 2.11% vs -1.19 ± 3.67%; RRMS: -1.74 ± 2.57% vs -1.74 ± 4.02%; PMS: -2.29 ± 2.40% vs -1.29 ± 3.20%) and healthy controls (0.02 ± 2.39% vs -0.56 ± 3.77%). GBSI performed better than CSA in differentiating healthy controls from CIS (area under the curve [AUC] = 0.66 vs 0.53; p = 0.03), RRMS (AUC = 0.73 vs 0.59; p < 0.001), PMS (AUC = 0.77 vs 0.53; p < 0.001), and patients with disability progression from patients without progression (AUC = 0.59 vs 0.50; p = 0.04). Sample size to detect 60% treatment effect on spinal cord atrophy over 1 year was lower for GBSI than CSA (CIS: 106 vs 830; RRMS: 95 vs 335; PMS: 44 vs 215; power = 80%; alpha = 5%). INTERPRETATION: The registration-based method (GBSI) allowed better separation between MS patients and healthy controls and improved statistical power, when compared with a conventional segmentation-based method (CSA), although it is still far from perfect. ANN NEUROL 2019 ANN NEUROL 2019;86:704-713.
引用
- Moccia M, Prados F, Filippi M, et al. Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. Ann Neurol. 2019. PMID: 31385358. doi:10.1002/ana.25571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。